Dual bronchodilation in real-life COPD management: analysis of patients’ characteristics enrolled in COPD Registry in Russia

Introduction: Dual bronchodilation (DB) is a core treatment approach in COPD management. Despite this, real-world data on current practice of DB are limited in Russia. Aims and Objectives: To assess the current clinical practice of DB prescription, disease characteristics and clinical profile of COPD patients based on real-world data. Methods: Data were obtained from the Russian COPD registry: a real-world observational study in outpatient sites (NCT02853383). Results: A total of 2,020 COPD patients were enrolled in the registry. 742 (37%) were treated by fixed DB combination: 43% indacaterol/glycopyrronium (IND/GLY), 42% olodaterol/tiotropium (OLO/TIO), 11% vilanterol/umeclidinium (VIL/UME), 4% formoterol/aclidinium (FOR/ACL). In DB group, the average age was 65.9±9.2 years, 75.5% were men. The mean pack-years of smoking was 39.1, 52% were current smokers. 51% of patients had GOLD B and 58% GOLD II (mean FEV1 58.5 ± 18.8%). The main reported phenotypes were chronic bronchitis (41%), emphysematous (27%), phenotype with cachexia (22%). Phenotype with frequent exacerbations was reported in 2%. The annual rate of COPD exacerbations was 1.05 for IND/GLY; 1.17 for OLO/TIO; 1.38 for VIL/UME and 1.73 for FOR/AKL. The most frequent comorbidities were arterial hypertension (51%), ischemic heart disease (34%), chronic heart failure (10%) and osteoporosis (3%). mMRC ≥ 2 was reported in 76% of patients. Conclusion: The majority of patients treated with DB were in GOLD II and GOLD B, highly symptomatic, with high level of cardio-vascular comorbidity and low risk of COPD exacerbations.